Longevity Biomedical (Longevity Biomedical) Piotroski F-Score

View and export this data going back to 2050. Start your Free Trial

What is Longevity Biomedical Piotroski F-Score?

Longevity Biomedical does not have enough data to calculate Piotroski F-Score.

Longevity Biomedical Piotroski F-Score Historical Data

The historical data trend for Longevity Biomedical's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longevity Biomedical Piotroski F-Score Chart

Longevity Biomedical Annual Data

Trend

Piotroski F-Score

Longevity Biomedical Semi-Annual Data

Piotroski F-Score

Longevity Biomedical (NAS:LBIO) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.

Longevity Biomedical Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Longevity Biomedical's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Longevity Biomedical (Longevity Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longevity Biomedical Inc (NAS:LBIO) » Definitions » Piotroski F-Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

12100 NE 195th street, Suite 150, Bothell, WA, USA, 98011

Website

https://www.longevitybiomedical.com

Longevity Biomedical Inc is a clinical-stage biomedical company. The company is focused on the advancement of new technologies across therapeutics, monitoring, and digital health that aim to restore tissue form and function to increase health span. Longevity is acquiring a differentiated therapeutic pipeline of late-stage clinical technologies across ophthalmology, cardiovascular disease, and soft tissue reconstruction and repair.

Longevity Biomedical (Longevity Biomedical) Headlines

No Headlines